Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: vytorin Clear all
Completed Phase 3 Interventional Results available

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

NCT00127218
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
any statin, niacin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 2, 2026, 2:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol

NCT00762164
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Vytorin, Simvastatin
Drug
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Sep 2, 2026, 2:10 PM EDT
Recruiting Phase 2 Interventional

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

NCT06437574
View directory record Official record
Conditions
Prostate Cancer
Interventions
Vytorin, Ezetimibe
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 2, 2026, 2:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects

NCT01420328
View directory record Official record
Conditions
Inflammation
Interventions
Vytorin, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 2, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 2, 2026, 2:10 PM EDT
Terminated Phase 3 Interventional

A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

NCT00267267
View directory record Official record
Conditions
Hyperlipidemia, Dyslipidemia
Interventions
torcetrapib/atorvastatin, ezetimibe/simvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
123
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2007 · Synced Sep 2, 2026, 2:10 PM EDT
Completed Phase 4 Interventional Results available

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.

NCT00988364
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Simvastatin, Vytorin, Placebo, Ezetimibe
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 2, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

Vytorin in the Treatment of Alopecia Areata

NCT01520077
View directory record Official record
Conditions
Alopecia Areata
Interventions
vytorin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 2, 2026, 2:10 PM EDT
Completed Not applicable Interventional Results available

Comprehensive Magnetic Resonance of Peripheral Arterial Disease

NCT00587678
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Simvastatin, Ezetimibe, Simvastatin/Ezetimibe
Drug
Lead sponsor
University of Virginia
Other
Eligibility
30 Years to 85 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 2, 2026, 2:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males

NCT02547402
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
CXA-10, pravastatin, Vytorin® (combination of simvastatin and ezetimibe)
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
19 Years to 30 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 2, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 2, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

NCT01047683
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 2, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes

NCT00477204
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Dyslipidemia
Interventions
Simvastatin, Ezetimibe/Simvastatin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 2, 2026, 2:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment

NCT00819403
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
simvastatin, ezetimibe/simvastatin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 2, 2026, 2:10 PM EDT
Completed Early Phase 1 Interventional

Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal

NCT02534376
View directory record Official record
Conditions
Prostate Cancer
Interventions
ezetimibe 10mg-simvastatin 40mg
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 2, 2026, 2:10 PM EDT